Specificities of IgE and IgG4 antibodies in 12 cat-allergic patients were compared with respect to their reactivity towards 3 IgE-binding synthetic peptides of Felis domesticus allergen 1 (Fel d I): peptides 25–38 and 46–59 of chain 1 and peptide 15–28 of chain 2. Peptides were coupled to Sepharose and anti-Feld I antibodies were isolated by affinity chromatography. Fel d I-specific IgE- and IgG4 antibody activity in the peptide eluates was measured using Fel d I binding assays. Fel d I-specific IgE/IgG4 ratios in the eluates from peptide-Sepharose were determined and compared with the IgE/IgG4 ratios in the eluates from Fel d I-Sepharose. The mean ratio Fel d I-specific IgE/IgG4 in the peptide eluates (0.84; range 0.06–4.6) was significantly higher than the mean ratio in the eluates from Fel d I-Sepharose (0.31; range 0.13–1.1), demonstrating a higher reactiviy of IgE antibodies with the peptides, compared to IgG4. These results indicate differences between the B cells producing IgE antibodies and the B cells producing IgG4 antibodies.

Keywords:
Cat, IgE antibody, IgG4 antibody, Peptide, Epitope
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.